TScan Therapeutics
TCRX
61 hedge funds and large institutions have $30.7M invested in TScan Therapeutics in 2025 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 19 reducing their positions, and 20 closing their positions.
7.45% less ownership
Funds ownership: 65.94% → 58.5% (-7.4%)
11% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 19
16% less funds holding
Funds holding: 73 → 61 (-12)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
50% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 20
51% less capital invested
Capital invested by funds: $62.9M → $30.7M (-$32.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$623K |
| 2 |
Renaissance Technologies
New York
|
+$450K |
| 3 |
Jane Street
New York
|
+$444K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$424K |
| 5 |
Two Sigma Investments
New York
|
+$335K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBM
Propel Bio Management
Los Angeles,
California
|
-$3.52M |
| 2 |
AI
Alphabet Inc
Mountain View,
California
|
-$1.96M |
| 3 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
-$1.65M |
| 4 |
Morgan Stanley
New York
|
-$900K |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$802K |
TCRX Hedge Fund Activity: Q4 2025 in Review
61 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q4 2025, worth a combined $30.7M — down 51% from $62.9M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of TCRX and 10 opened new positions — a net loss of 10 holders — while 19 trimmed existing stakes and 17 added.
The largest buyer was Aberdeen Group, adding an estimated $623K. The largest seller was Propel Bio Management, exiting entirely with an estimated $3.52M sold.
- 61 institutional investors held TScan Therapeutics (TCRX) as of Q4 2025, down from 73 in Q3 2025.
- Funds reported $30.7M of TScan Therapeutics stock for Q4 2025, down 51% quarter-over-quarter.
- 10 funds opened new TScan Therapeutics positions in Q4 2025 and 20 closed out, a net change of -10 holders.
- The largest TScan Therapeutics buyer in Q4 2025 was Aberdeen Group, an estimated $623K added.
- The largest TScan Therapeutics seller in Q4 2025 was Propel Bio Management, an estimated $3.52M sold.
Based on aggregated 13F filings for Q4 2025.